The latest installment in BioPharma Dive’s data visualization series features a closer look at Novo's stock performance and the recent run of fundraising success for AI drug discovery startups.
Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli ...
ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in ...
Panel members said the first-of-a-kind blood test should not be used to replace medical guideline-recommended cancer ...
Pressed by lawmakers on Thursday, Trump’s pick as the next FDA chief said she’d “follow the law” on key decisions and work to speed early drug research.
A medicine acquired in a $1.3 billion buyout came through in the first of two pivotal studies in diabetic macular edema, ...
Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded ...
Enveda, which is using AI tools to mine plants and microbes for drug prospects, has three candidates in human testing for ...
The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results